The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Prevalence of HPV After Introduction of the Vaccination Program in the United States
Abstract
BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been recommended for females aged 11 to 12 years and through 26 years if not previously vaccinated. METHODS: HPV DNA prevalence was analyzed in cervicovaginal specimens from females aged 14 to 34 years in NHANES in the prevaccine era (2003–2006) and 4 years of the vaccine era (2009–2012) according to age group. Prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV-6, -11, -16, and -18) and other HPV type categories were compared between eras. Prevalence among sexually active females aged 14 to 24 years was also analyzed according to vaccination history. RESULTS: Between the prevacccine and vaccine eras, 4vHPV type prevalence declined from 11.5% to 4.3% (adjusted prevalence ratio [aPR]: 0.36 [95% confidence interval (CI): 0.21–0.61]) among females aged 14 to 19 years and from 18.5% to 12.1% (aPR: 0.66 [95% CI: 0.47–0.93]) among females aged 20 to 24 years. There was no decrease in 4vHPV type prevalence in older age groups. Within the vaccine era, among sexually active females aged 14 to 24 years, 4vHPV type prevalence was lower in vaccinated (≥1 dose) compared with unvaccinated females: 2.1% vs 16.9% (aPR: 0.11 [95% CI: 0.05–0.24]). There were no statistically significant changes in other HPV type categories that indicate cross-protection. CONCLUSIONS: Within 6 years of vaccine introduction, there was a 64% decrease in 4vHPV type prevalence among females aged 14 to 19 years and a 34% decrease among those aged 20 to 24 years. This finding extends previous observations of population impact in the United States and demonstrates the first national evidence of impact among females in their 20s.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Prevalence of HPV Infection Among Females in the United States
Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., & Markowitz, L. E. (2007) · JAMA · doi:10.1001/jama.297.8.813 · Cited by 1,579
Self-citationA 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., Chow, S.-N., Apter, D. L., Kitchener, H. C., Castellsague, X., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60946-5 · Cited by 1,315
Petrosky, E. Y., Bocchini, J. A., Hariri, S., Chesson, H. W., Curtis, C. R., Saraiya, M., Unger, E. R., & Markowitz, L. E. (2015) · PubMed · Cited by 1,047
Self-citationLe, M., Dunne, E. F., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J. M., Bocchini, J. A., & Unger, E. R. (2014) · PubMed · Cited by 924
Self-citationDesign and estimation for the National Health Interview Survey, 1995-2004
Botman, S., & Moriarity, C. L. (2000) · Cited by 785
US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Saraiya, M., Unger, E. R., Thompson, T. D., Lynch, C. F., Hernandez, B. Y., Lyu, C. W., Steinau, M., Watson, M., Wilkinson, E. J., Hopenhayn, C., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv086 · Cited by 761
Self-citationA review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Drolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Self-citation
Cited by
Drolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M.-C., Baldo, V., Brassard, P., Brotherton, J. M. L., Callander, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30298-3 · Cited by 1,384
Self-citationCervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2018
Kreisel, K. M., Spicknall, I. H., Gargano, J. W., Lewis, F. M. T., Lewis, R. M., Markowitz, L. E., Roberts, H., Johnson, A. S., Song, R., St. Cyr, S. B., et al. (2021) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001355 · Cited by 530
Self-citationSurveillance of vaccination coverage among adult populations—United States, 2015.
Williams, W. W., Lu, P.-J., O’Halloran, A., Kim, D. K., Grohskopf, L. A., Pilishvili, T., Skoff, T. H., Nelson, N. P., Harpaz, R., Markowitz, L. E., et al. (2017) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6611a1 · Cited by 442
Self-citationChaturvedi, A. K., Graubard, B. I., Broutian, T., Pickard, R. K. L., Tong, Z.-Y., Xiao, W., Kahle, L., & Gillison, M. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.0141 · Cited by 320
Metadata
- Authors
- Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2016-03-01
- Volume
- 137
- Issue
- 3
- Pages
- e20151968-e20151968
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2279505249
- Cited by
- 383
- References
- 31
- FWCI
- 57.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of HPV After Introduction of the Vaccination Program in the United States. https://app.cochat.ai/papers/10.1542/peds.2015-1968
- The paper
- Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016). Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. https://doi.org/10.1542/peds.2015-1968
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.